Answers are grounded in this paper and cite their sources.
rATG induction therapy may lead to improved renal function and lower rejection rates following liver transplant. The use of this medication can help avoid unwanted adverse effects from other immunosuppression agents. Because of the potential benefits with this induction agent, rATG may have a larger role in induction therapy for liver transplant recipients.
No takes yet. Share an insight, caveat, or question.
Petite et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: